Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Cash from Financing Activities: 2012-2025

Historic Cash from Financing Activities for CorMedix (CRMD) over the last 9 years, with Sep 2025 value amounting to $150.5 million.

  • CorMedix's Cash from Financing Activities rose 969.55% to $150.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $251.2 million, marking a year-over-year increase of 1029.57%. This contributed to the annual value of $26.3 million for FY2024, which is 52.93% down from last year.
  • Per CorMedix's latest filing, its Cash from Financing Activities stood at $150.5 million for Q3 2025, which was up 80.83% from $83.2 million recorded in Q2 2025.
  • In the past 5 years, CorMedix's Cash from Financing Activities ranged from a high of $150.5 million in Q3 2025 and a low of -$97,118 during Q1 2024.
  • For the 3-year period, CorMedix's Cash from Financing Activities averaged around $34.2 million, with its median value being $9.2 million (2023).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first plummeted by 101.35% in 2024, then spiked by 7,778.42% in 2025.
  • Over the past 5 years, CorMedix's Cash from Financing Activities (Quarterly) stood at $176,992 in 2021, then skyrocketed by 4,652.28% to $6.0 million in 2022, then surged by 139.68% to $7.2 million in 2023, then tumbled by 101.35% to $11.3 million in 2024, then skyrocketed by 969.55% to $150.5 million in 2025.
  • Its last three reported values are $150.5 million in Q3 2025, $83.2 million for Q2 2025, and $6.1 million during Q1 2025.